SWK Holdings Q2 2020 Life Science Financing Shareholder Presentation

SWK Holdings presents its specialty finance and asset management approach to life science financing, targeting $5-20mm commercial-stage healthcare company financings and royalty monetizations. The company highlights 36 completed financings deploying $540mm with a portfolio yield of 13.2% and a 10% book value per share CAGR strategy. SWK aims to serve as a partner of choice for life sciences companies seeking financing of $20mm or less while generating current income.